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“being too busy (2.5% Medicare; 17.2% commercial and “other reasons” (21.9% 
Medicare; 8.1% commercial) which included travel, being hospitalized or sick, disrup-
tion of daily events and unable to get to the pharmacy. Prescription copay was a 
barrier for <5% of respondents. Taking medications as part of a daily routine (46.4% 
Medicare; 52.2% commercial) helped improve adherence. Low non adherence 
(0–59%) was associated with higher cardiovascular related expenditures ($11,800) 
compared to moderate (60–79%) non adherence ($8467). CONCLUSIONS: Despite 
elaborate models explaining non adherence, forgetfulness was the primary reason for 
self reported non-adherence in this study. Events interfering with daily routine also 
had signiﬁcant impact on non-adherence. Novel interventions should address medica-
tion taking competency and promote a medication routine.
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PREDICTORS OF CLOPIDOGREL USE AND ADHERENCE FOR PATIENTS 
WITH ACUTE CORONARY SYNDROMES IN A LARGE EMPLOYER-BASED 
CLAIMS DATABASE
Zhu B, Zhao Z, McCollam P, Anderson J, Bae J, Zettler M, LeNarz L
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Dual-antiplatelet therapy with aspirin and thienopyridines is consid-
ered as the cornerstone in the treatment of acute coronary syndromes (ACS) undergo-
ing percutaneous coronary intervention (PCI). Recent ACC/AHA/SCAI guidelines on 
PCI recommend the use of clopidogrel or prasugrel for the treatment of ACS patients 
undergoing PCI with drug eluting or bare metal stents for at least a year. However, 
little is known about the factors that predict the use and adherence of clopidogrel in 
ACS-PCI patients. This study examined the predictors of clopidogrel use and adher-
ence in the employer-based MarketScan claims database. METHODS: Patients (N = 
10,456), aged 18–65 years, hospitalized with a primary diagnosis of ACS and under-
went PCI between January 1, 2005 and December 31, 2006, and had a prior 1-year 
insurance eligibility and drug information were identiﬁed. Adherence was deﬁned as 
medication possession ratio (MPR) of ≥80%. Multivariate logistic regression analyses 
were conducted to identify the predictors of clopidogrel use and adherence. RESULTS: 
Overall, 92.8% of ACS-PCI patients received a prescription of clopidogrel and 66.8% 
of the clopidogrel users were adherent. Receiving PCI without stenting (OR = 3.3), 
comorbid hypertension (OR = 1.50), diabetes (OR = 1.49), atrial ﬁbrillation (OR = 
1.87), and older age (OR = 1.01) were associated with decreased use of clopidogrel 
while prior use of clopidogrel (OR = 0.54) or other BASI (Beta-blocker, Antiplatelet 
agents, Statin, and ACE Inhibitor) (OR = 0.43) were associated with increased use of 
clopidogrel (all p-values <0.05). Factors signiﬁcantly associated with non-adherence 
of clopidogrel were: prior use of clopidogrel (OR = 1.41), prior hospitalization (OR 
= 1.34), chronic pulmonary disease (OR = 1.33), PCI without stenting (OR = 1.33), 
and diabetes (OR = 1.18). Older age (OR = 0.98) and prior use of other BASI medica-
tions (OR = 0.84) increased the adherence of clopidogrel. CONCLUSIONS: Prior use 
of clopidogrel and other heart medications, stenting, diabetes and other comorbidities 
affected the use and adherence of clopidogrel by ACS patients undergoing PCI. These 
ﬁndings may help programs that aim to improve thienopyridines adherence for 
increased effectiveness.
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PATIENT ADHERENCE TO CHRONIC DISEASE MEDICATIONS IN  
A MEDICATION THERAPY MANAGEMENT PROGRAM
Ramasamy A1, Pinto S2, Holiday-Goodman M2, Black CD2
1Forest Research Institute, Jersey City, NJ, USA, 2University of Toledo, Toledo, OH, USA
OBJECTIVES: 1) To evaluate adherence to chronic disease (Diabetes, Hypertension, 
and Hyperlipidemia) medications of patients enrolled in an employer sponsored Medi-
cation Therapy Management (MTM) program. 2) To determine the effect of adherence 
on the clinical outcomes of patients with diabetes and hypertension in the MTM 
program. METHODS: This was a retrospective, longitudinal study. Adherence data 
was obtained from an independent pharmacy participating in an employer sponsored 
MTM program in the form of pharmacy reﬁll records for 272 patients. Clinical data 
was obtained through patient chart reviews. Medication adherence was calculated 
using Medication Possession Ratio (MPR) and weighted average adherence was cal-
culated for each class of medications. Pearson correlation was used to determine the 
relationship between medication adherence and desired clinical outcomes-HbA1c for 
diabetic patients and mean arterial pressure for hypertension patients. Multiple linear 
regression was used to determine if medication adherence was a predictor of clinical 
outcomes. Data analysis was performed using SPSS version16.0 and Microsoft Excel. 
RESULTS: Pearson correlation results indicated that MPR to diabetic medications 
was signiﬁcantly correlated with age (r = 0.387, p = 0.000) and gender (r = −0.167, 
p = 0.021). Further, age was signiﬁcantly correlated with number of diseases (r = 
0.278, p = 0.000) among diabetic patients. However, there were no signiﬁcant predic-
tors of change in A1c among diabetic patients. Among hypertension patients, change 
in mean arterial pressure was signiﬁcantly correlated with gender (r = 0.123 p = 0.037) 
and MPR (r = −0.146, p = 0.013). MPR was also found to be signiﬁcantly correlated 
with gender (r = −0.148, p = 0.012, co-pay (r = 0.142, p = 0.016), and number of 
diseases (r = 0.142, p = 0.016). Regression model for hypertension patients indicated 
that MPR (β = −0.136, p = 0.024) was a signiﬁcant predictor of change in mean arterial 
pressure. CONCLUSIONS: Patients enrolled in an employer sponsored MTM 
program showed high weighted average adherence to most of the classes of diabetes, 
hypertension, and hyperlipidemia medications. This study also identiﬁed predictors of 
clinical outcomes associated with diabetes and hypertension.
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PATTERNS AND PREDICTORS OF PERSISTENCE OF WARFARIN AND 
OTHER COMMONLY-UTILIZED CHRONIC MEDICATIONS AMONG 
PATIENTS WITH ATRIAL FIBRILLATION
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OBJECTIVES: We examined the patterns of persistence among warfarin and other 
common chronic medications in patients with atrial ﬁbrillation (AF) and identiﬁed 
predictors of warfarin non-persistence. METHODS: We used a national, managed 
care claims dataset (January 1, 2005-December 31, 2007) to evaluate patterns of 
persistence in patients with AF. We examined those that ﬁlled a prescription for 
warfarin within 3 months following AF hospitalization discharge and had at least 
12-month continuous data prior to and following the ﬁrst ﬁll. For comparison, we 
also evaluated patterns of persistence for other selected, chronically-prescribed medi-
cations, including branded, generic, once-, twice-, and thrice-daily medications. Non-
persistence was deﬁned as failure to reﬁll the medication within 60 days from the 
run-out date of the prior prescription. Survival models were used to identify predictors 
of warfarin non-persistency. RESULTS: A total of 28,384 patients with AF were 
identiﬁed; 16,036 (56.5%) ﬁlled a warfarin prescription shortly following hospitaliza-
tion for AF. A total of 53.5% of warfarin users were persistent on warfarin for at 
least 1 year. Among non-persistent patients, average time to non-persistence was 122 
(SD 83) days from the ﬁrst warfarin prescription. Persistence with pioglitazone, sita-
gliptin, amlodipine, and once- and twice-daily carvedilol were similar to warfarin. 
While persistence with twice-daily carvedilol was similar to once-daily carvedilol 
phosphase (60.1% vs. 61.3%, p = 0.680), persistence of thrice-daily captopril was 
signiﬁcantly worse than that of once-daily amlodipine (27.7% vs. 51.9%, p < 0.001). 
Factors signiﬁcantly associated with time to non-persistence with warfarin included 
age, gender, residence in the south and west region, ischemic stroke, urinary tract 
infection, and warfarin out-of-pocket expense. CONCLUSIONS: Persistence with 
warfarin among patients with AF is consistent with other chronic medications. Per-
sistence with thrice-daily, but not twice-daily therapy was worse than once-daily 
medication. Factors associated with non-persistence can be used to identify patients 
and target adherence programs.
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DISCRIMINATORY POWER OF THE KCCQ IN ESTIMATING HEALTH 
UTILITIES IN HEART FAILURE PATIENTS
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OBJECTIVES: Most economic models in heart failure have been structured using New 
York Heart Association (NYHA) class to deﬁne mutually exclusive health states. With 
this structure, no utility (i.e. effectiveness) gains are measured in patients who experi-
ence important changes in health status but remain in the same NYHA class. We 
sought to evaluate whether the Kansas City Cardiomyopathy Questionnaire (KCCQ) 
summary score can further discriminate between patients with lower and higher health 
utilities within a given NYHA class. METHODS: Repeated measures of NYHA class, 
KCCQ, and EQ-5D utility scores were available from patients enrolled in HF-
ACTION, a randomized trial evaluating the effectiveness and safety of exercise train-
ing in addition to usual care compared to usual care alone in patients with chronic 
heart failure. We used generalized estimating equations to regress utility scores on 
NYHA class and demographic characteristics and to evaluate the impact of adding 
the KCCQ summary score in the regression models.RESULTS: A total of 12,649 sets 
of assessments were available from 2331 patients. The mean age of the study cohort 
was 59 years at baseline, 72% were male, 61% were white, and 32% were black. 
When controlling for age, gender and race, estimated utilities were 0.84 (95% CI: 
0.81–0.87) for NYHA class I, 0.80 (95% CI: 0.78–0.83) for class II, 0.75 (95% CI: 
0.72–0.78) for class III, and 0.65 (95% CI: 0.61–0.69) for class IV. A one-unit increase 
in the KCCQ summary score was associated with a 0.0044 (95% CI: 0.0042, 0.0045) 
increase in the utility weight, and its impact did not signiﬁcantly vary across NYHA 
classes. CONCLUSIONS: Use of KCCQ summary score in addition to, or instead of, 
NYHA class may provide more discriminatory power in terms of estimating incre-
mental gains in quality-adjusted life-years afforded by interventions for heart failure.
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CLINICAL ENDPOINTS
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OBJECTIVES: To demonstrate a simple, powerful, and ﬂexible approach to modeling 
the relationships between patient-reported outcomes and clinical measures over time. 
METHODS: Data were from 2,331 patients enrolled in the HF-ACTION (Heart 
Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing) trial. 
The patient-reported endpoint was the Kansas City Cardiomyopathy Questionnaire 
(KCCQ) overall score and the clinical endpoint was peak VO2. We compared three 
different ways of measuring the association between changes in the KCCQ and peak 
VO2. The ﬁrst method (SIMPLE) computes change-from-baseline scores for each 
outcome. The second method (BLUP-1) used a linear mixed-effects model for each 
outcome to derive the best linear unbiased predictions (BLUP) of changes from 
baseline. The third method (BLUP-2) added 28 baseline covariates and their interac-
tions with time to the mixed model and then obtained BLUPs. For all three methods 
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we calculated Pearson correlations between changes in KCCQ and Peak VO2 at 3 
and 12 months. Conﬁdence intervals of r’s were estimated via bootstrapping. 
RESULTS: The SIMPLE method produced a wider distribution of change scores 
than the other two methods. However, compared to BLUP-1 and BLUP-2, the 
SIMPLE method estimated lower correlations between changes in KCCQ and Peak 
VO2 at both 3 and 12 months: At 3 months, SIMPLE r (95% CI) = .16 (.11, .21), 
BLUP-1 r = .28 (.18, .38), and BLUP-2 r = .29 (.22, .40). At 12 months, SIMPLE 
r = .22 (.15, .27), BLUP-1 r = .27 (.21, .33), and BLUP-2 r = .31 (.25, .40). CON-
CLUSIONS: Compared to the SIMPLE approach, the BLUP approach has the fol-
lowing advantages: 1) uses all of the longitudinal data available; 2) estimates with 
reasonable assumptions about missing data; 3) accommodates nonlinear and differing 
longitudinal trajectories for the PRO and clinical measures; and 4) minimizes the 
inﬂuence of noisy data.
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RESPONSIVENESS OF AF6, A NEW, SHORT, VALIDATED, AF-SPECIFIC 
QUESTIONNAIRE—SYMPTOMTIC BENEFIT OF DC CARDIOVERSION
Edvardsson N1, Härdén M2, Nyström B2, Bengtson A2, Medin J3, Frison L3
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OBJECTIVES: The aim was to measure the effects on symptoms of a direct current 
cardioversion (DC) in patients with atrial ﬁbrillation (AF) with a new, short, validated 
AF-speciﬁc questionnaire, the AF6. METHODS: One hundred and eleven patients (89 
men, 22 women) were included in the study. Their symptoms were screened before 
and 12 ± 3 days after DC, using AF6, consisting of 6 items, representing the most 
common symptoms or experiences of patients in an AF clinic. Symptom scores were 
analyzed in the whole study population as well as in clinical responders and non-
responders, using sinus rhythm (SR) at follow-up as a clinical anchor. RESULTS: The 
total mean score in the study population decreased, (18 ± 12.4 to 13 ± 11.6, p < 
0.0001), and in responders (n = 56), (22 ± 14 vs. 12 ± 12, p < 0.01), but not in non-
responders (n = 55), 14 ± 9 vs. 14 ± 11, N.S. The highest scoring items were ´breathing 
difﬁculties upon exertion´ and ´tiredness due to atrial ﬁbrillation´, and they were also 
the most frequently scoring items (80% and 83%, respectively). The other items of 
the scale were present in 65%, 64%, 48% and 36% of the patients. ´Worry/anxiety 
due to atrial ﬁbrillation´ was present in 48% of the patients, scoring high when 
present. ´Breathing difﬁculties at rest´ was the least and the lowest scoring item. Effect 
sizes ranged from 0 to 0.52, in responders from 0.10 to 0.85, and in non-responders 
from −0.23 to 0.34, the highest scores consistently relating to ´tiredness due to atrial 
ﬁbrillation. CONCLUSIONS: AF6 demonstrated adequate responsiveness to change, 
and effect sizes were mostly moderate, in responders moderate to high. The symptom 
scores measured by AF6 decreased signiﬁcantly after DC cardioversion, especially in 
responders in terms of SR, conﬁrming, that SR is an important clinical anchor.
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IMPACT OF STROKE ETIOLOGY ON CARE NEED AND LONG-TERM 
OUTCOMES
Kolominsky-Rabas P, Dietl M, Graessel E, Drexler H, Schwab S
University of Erlangen-Nurnberg, Erlangen, Germany
OBJECTIVES: Stroke is the second leading cause of death worldwide and a major 
cause of long-term disability. Increasingly, stroke outcomes research is following clini-
cal practice and not only considers all strokes together but divides them into various 
risk-proﬁle subtypes. Following this approach, we performed a population-based 
study of all residents of Erlangen, Bavaria, Germany, to determine the risk proﬁle 
distributions in a well-deﬁned population and their long-term impact on disability and 
patterns of care. METHODS: Since 2000 the Erlangen Stroke Project (ESPro) is the 
reporting centre for stroke for the German Federal Government. As the only popula-
tion-based stroke registry in Germany ESPro is recording each patient living in Erlan-
gen, Bavaria, Germany (source population 100,500) who suffered from stroke. The 
patients were analysed at time points after admission as well as 3 and 12 month after 
the event. A total of 1355 patients with a ﬁrst-stroke were registered in the ESPro. 
The cause of ischemic stroke was classiﬁed according to the TOAST criteria. Etiologi-
cal TOAST classiﬁcation was performed in 89% (1206) of ischemic strokes. RESULTS: 
The etiological classiﬁcation of brain infarctions resulted in 12% large-artery athero-
sclerosis, 26% cardioembolism, 24% small-artery occlusion, 37% strokes of undeter-
mined etiology and 2% strokes of other determined etiology. While 20% of the 
patients were independent functionally at the Barthel index at admission, the number 
was 39% after 12 month. The category large-artery atherosclerosis showed the stron-
gest relationship with the occurring need of care. The OR with very strong care needs 
12.79 (95% CI3.71 –44.07) lay particularly high in comparison with an OR of 6.95 
(95% CI 2.16–22.33) in the category cardioembolism. CONCLUSIONS: The TOAST 
classiﬁcation provides an appropriate tool for estimating the need of care. In particular 
the patients in the TOAST category large-artery atherosclerosis showed a high level 
of a need of care at the long-term follow-up.
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HEALTH-RELATED QUALITY OF LIFE AMONG WOMEN WITH 
CORONARY ARTERY DISEASE TREATED WITH PSYCHOTROPIC 
MEDICATIONS
Viswanathan S, Gemmen E, Bharmal M
Quintiles, Falls Church, VA, USA
OBJECTIVES: Recent studies have found that the use of psychotropic medications in 
women with coronary artery disease (CAD) led to long-term adverse outcomes such 
as cardiovascular adverse events. This study examined the effect of psychotropic 
medication use on the health-related quality of life (HRQoL) of women with CAD. 
METHODS: Analysis was conducted using the 2007 Medical and Expenditure Panel 
Survey (MEPS) database, which is nationally representative of the US civilian non-
institutionalized population. Female patients >= 18 years with CAD were included in 
this analysis. CAD patients were identiﬁed using a combination of International Clas-
siﬁcation of Diseases (ICD-9) diagnosis codes. HRQoL was measured using the Physi-
cal Component Summary (PCS-12) and Mental Component Summary (MCS-12) of 
the Short-Form 12 Version 2 (SF-12). HRQoL and sociodemographic characteristics 
of female CAD patients who used at least one psychotropic medication were compared 
with those who did not use any psychotropic medications. Bivariate comparisons were 
made using t-tests for continuous variables and chi-square tests for categorical vari-
ables. Multivariate comparisons using analysis of covariance (ANCOVA) models were 
conducted to assess the association of HRQoL with psychotropic use after adjusting 
for age, race, education, marital status, insurance status, and the number of medical 
conditions in 2007. RESULTS: Of the 4,253,569 women with CAD in the US, 
1,312,413 (30.9%) took psychotropic medications. Women taking psychotropic medi-
cations reported a signiﬁcantly higher number of medical conditions compared to 
non-users (13.25 vs. 9.51, p < 0.0001). The mean unadjusted differences in PCS-12 
and MCS-12 scores between psychotropic drug users versus non-users suggested worse 
scores among women taking psychotropic medications (PCS-12: −4.93; p = 0.03 and 
MCS-12: −9.46; p = 0.0006), and this trend in differences continued after adjusting 
for covariates (PCS-12: −2.23; p = 0.26 and MCS-12: −7.51; p = 0.0034). CONCLU-
SIONS: Consistent with ﬁndings of long-term adverse outcomes from previous studies, 
psychotropic medication use among women with CAD was associated with signiﬁ-
cantly worse HRQoL.
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A SYSTEMATIC REVIEW OF QUALITY OF LIFE ASSESSMENT OF 
PATIENTS SUFFERING FROM THORACIC AORITC DISEASES
Brasseur P1, Sidhu R2
1Medtronic International SA, Tolochenaz, Vaud, Switzerland, 2LSE, London, UK
OBJECTIVES: To review studies assessing the quality of life associated with thoracic 
aortic diseases (TADs) and their treatment with Open Aortic Repair (OAR), Thoracic 
Endovascular Aortic Repair (TEVAR) or medical management (MM). METHODS: 
PubMed and EMBASE were searched covering terms related to TADs and patient 
reported outcomes/quality of life. The search was limited to articles in English and to 
studies relating to humans. However, no time period was speciﬁed so as to enable a 
broad search. The studies obtained were analysed qualitatively. RESULTS: Eight 
studies met the review criteria. Published 1998 and 2009, four dealt with aneurysms, 
two with dissections and two with more than one of the TADs; all of them were based 
on assesment of quality of life after treatment rather than on the disease itself. Only 
one study covered emergency versus elective surgery. The number of patients was very 
small in all studies, ranging from 75 to 11. Mean follow-up varied from 7 to 76 
months. The most commonly used instrument was the SF-36. Two studies also used 
the Hospital Anxiety and Depression Score (HADS) in addition to the SF-36. One 
study adopted the SWEDQUAL questionnaire ; another study had recourse to the 
Illness Intrusiveness Rating Scale (IIRS) and the Karnofsky Activity Scale (KAS), which 
lacked information on proper validation for this target population. All in all, none of 
the study conducted the quality of life assessment appropriately, particularly with 
regard to the follow-up period, the lack of pre-operative assessment and lack of direct 
comparison between interventions. Lastly, there were no utility assessments to be 
found, which would be essential to arrive at QALY values and thus take the process 
of economic analysis forward. CONCLUSIONS: The studies available so far do not 
provide evidence of the quality of life associated with TADs, as well as conclusive 
evidence of the quality of life associated with OAR; TEVAR and/or MM.
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HEALTH-RELATED QUALITY OF LIFE OF DIABETES PATIENTS WITH 
AND WITHOUT MACROVASCULAR COMORBIDITIES IN THE UNITED 
STATES
Qiu Y1, Fu AZ2, Radican L1
1Merck & Co., Inc., Whitehouse Station, NJ, USA, 2Cleveland Clinic, Cleveland, OH, USA
OBJECTIVES: Diabetes mellitus has been deﬁned as one of the global epidemics of 
chronic diseases by the World Health Organization. Patients with diabetes are at an 
increased risk of developing macrovascular disease. The purpose of this study was to 
examine the marginal impact of macrovascular comorbidities on health-related quality 
of life (HRQoL) of patients with diabetes in a United States nationally representative 
sample. METHODS: Using the pooled Medical Expenditure Panel Survey (MEPS) 
2001 and 2003 data, a nationally representative adult sample (age ≥18) was included 
in the study. The HRQoL outcomes included the SF-12 physical component summary 
(PCS) score, SF-12 mental component summary (MCS) score, EQ-5D preference-based 
index score, and visual analog scale (VAS). Ordinary least square regressions were 
used to identify the relationship between macrovascular disease conditions and PCS 
(and MCS) after controlling for age, sex, race, ethnicity, education, income, smoking 
status, health insurance, proxy response, and number of other comorbid categories. 
Due to the distributions of the EQ-5D preference-based index and VAS score, censored 
linear deviations estimator (CLAD) regressions were employed. All statistics were 
adjusted using the proper sampling weight from the MEPS. RESULTS: The average 
PCS, MCS, EQ-5D index, and VAS scores for patients with diabetes were 40.5, 48.5, 
0.75, and 66.6, respectively for the sample. Compared to diabetes patients without 
macrovascular comorbidities (N = 2,809), those with macrovascular comorbidities (N 
